India  

Serum Institute of India

Indian biotechnology and biopharmaceuticals company

Serum Institute of India    ▸ Facts   ▸ Comments   ▸ News   ▸ Videos   

Serum Institute of India: Indian biotechnology and biopharmaceuticals company
Serum Institute of India (SII) is an Indian biotechnology and biopharmaceuticals company. It is the world's largest manufacturer of vaccines located in the city of Pune, India and was founded by Cyrus Poonawalla in 1966. The company is a subsidiary of the holding company Poonawalla Investment and Industries.

0
shares
ShareTweetSavePostSend
 

You Might Like


India allows Serum Institute to enrol 7-11 year olds in Covid-19 vaccine trial

India's drug regulator on Tuesday allowed vaccine maker Serum Institute to enrol kids aged 7-11 years for its Covid-19 vaccine trial as the country prepares to protect children from the coronavirus...
IndiaTimes - Published

India warns UK of reciprocal steps over vaccine ‘discrimination’

“Covishield is a licensed product of the UK company, manufactured in India of which we have supplied five million doses to the UK,” said Shringla, pointing to the inconsistency in the rules..
IndiaTimes - Published

PM Modi, Mamata Banerjee and SII CEO Poonawala in TIME Magazine's '100 most influential people of 2021' list

PM Narendra Modi, along with Mamata Banerjee and Adar Poonawala, has secured a place in TIME Magazine's '100 most influential people of 2021' list.
DNA - Published Also reported by •IndiaTimes

SII to supply Inactivated Polio Vaccine to Centre for Universal Immunisation Programme from September


IndiaTimes - Published

Centre places purchase order with Serum Institute for 66 crore Covishield doses to be supplied by Dec: Sources


IndiaTimes - Published

SII chairman Cyrus Poonawalla against using cocktail of Covid-19 vaccines


IndiaTimes - Published

136 crore Covishield, Covaxin doses to lead India's vaccination drive during August-December

More than 136 crore Covid-19 vaccine doses are expected to be available till the end of this year, informed the Centre. For the next four months, India's vaccine programme will be accelerated by the..
IndiaTimes - Published

Sputnik V vaccine production in India to go fully on stream in September: RDIF

The production of Sputnik V in India is expected to come fully on stream in September. "Production in India is expected to come fully onstream in September and RDIF expects India to become a major..
IndiaTimes - Published

17 European nations have given nod to Covishield: Serum Institute of India


IndiaTimes - Published

No application received from SII for EU authorisation of Covishield vaccine: EMA

Poonawalla last month said that he was 'taking this up at the highest levels with regulators and diplomats' and that he hoped to resolve this matter.
DNA - Published Also reported by •IndiaTimes

Serum Institute to start production of Sputnik V vaccine from September

As part of the technology transfer process, SII has already received cell and vector samples from the Gamaleya Center, which developed the jab.
DNA - Published Also reported by •IndiaTimes

Switzerland, Iceland, 7 EU nations approve Covishield for travel entry

Switzerland, Iceland and seven EU countries have approved Covishield, the AstraZeneca vaccine manufactured by Serum Institute of India, a day after India threatened to put European visitors under..
IndiaTimes - Published

'Submit results on Covavax adult trials first': Govt panel to SII on Covid-19 vaccine trials for children


IndiaTimes - Published

Govt panel recommends against allowing SII to conduct trial of Covovax on children aged 2-17 yrs

An expert panel of the country's central drug authority on Wednesday recommended against granting permission to the Serum Institute of India (SII) to conduct the phase 2/3 trial of Covid-19 vaccine..
IndiaTimes - Published

Adar Poonawalla says EU green pass Covishield issue has been ‘blown out of proportion’

Serum Institute of India CEO Adar Poonawalla played down on Wednesday Covishield not getting approved for the EU green pass, saying, "It is not a controversy at all. It’s been blown out of..
IndiaTimes - Published

'Matter of time': SII's Poonawalla confident of getting EU green pass for Covishield

Serum Institute of India (SII) CEO Adar Poonawalla on Wednesday said that the European approval for its locally manufactured Covishield vaccine is "just a matter of time" and is expected in about a..
IndiaTimes - Published

Covishield not a ‘green pass’, Europe-bound Indians fret

BENGALURU: The exclusion of Covishield, AstraZeneca’s Covid-19 vaccine manufactured by Pune-based Serum Institute of India, from the European Union’s Covid ‘Green Pass’ has left hundreds of..
IndiaTimes - Published

Serum Institute CEO Adar Poonawalla breaks silence on India's Covishield yet to get European Union 'Green Pass'

Indians who are vaccinated with the Covishield may not be eligible for the European Union's 'Green Pass', according to reports.
DNA - Published

Serum Institute's COVID-19 vaccine 'Covovax' likely to launch by September

The new vaccine shall be launched under the brand name of Covovax, which SII is manufacturing in partnership with US pharmaceutical firm Novovax.
DNA - Published

SII, Bharat Biotech seek hike in government price for Covid vaccines

Serum Institute of India (SII) and Bharat Biotech (BB) are seeking higher prices for Covid-19 vaccines from the Centre amid concerns that the cost of Covishield and Covaxin shots in private hospitals..
IndiaTimes - Published

COVID-19: Serum Institute's Novavax vaccine shows 90% overall efficacy

Novavax in collaboration with Indian drug manufacturer Serum Institute of India is manufacturing these vaccines for India and low-income countries.
DNA - Published

Covid-19: Novavax set for India launch with Serum Institute of India as manufacturing partner

The uncertain path to authorisation in the US for Novavax despite passing the efficacy test with an impressive score of 90.4% might see India emerge as a major destination for the shots with the Serum..
IndiaTimes - Published

Covishield produces more antibodies than Covaxin, finds study

Covishield, from the Oxford-AstraZeneca stable, is manufactured by the Serum Institute of India in Pune. Covaxin is the indigenously manufactured vaccine by Hyderabad-based Bharat Biotech in..
IndiaTimes - Published

COVID-19: DCGI approves Serum Institute to manufacture Sputnik V vaccine in India

SII has collaborated with Gamaleya Research Institute of Epidemiology and Microbiology, Moscow in Russia for developing Sputnik V.
DNA - Published

Serum Institute gets DCGI's nod to manufacture Covid jab Sputnik V in India


IndiaTimes - Published Also reported by •DNA

Serum Institute of India pushes for indemnity after foreign companies’ request


IndiaTimes - Published

US to ease Covid vaccine input supply: Kamala Harris to PM Modi

US Vice-President Kamala Harris on Thursday spoke to PM Narendra Modi to brief him about the Biden administration’s new vaccine policy that will clear supply chains for AstraZeneca and Novavax..
IndiaTimes - Published

Serum Institute seeks indemnity from liability; says 'rules should be same for everyone': Sources


IndiaTimes - Published

After Pfizer, Serum Institute seeks indemnity over Covid-19 vaccine: Sources

Amid discussions over possible legal protection to foreign vaccine manufacturers Pfizer and Moderna over their Covid-19 jabs in India, the Serum Institute of India (SII) has also sought protection..
IndiaTimes - Published

HC asks Maharashtra to address security concerns raised by SII CEO


IndiaTimes - Published

SII unable to supply Covishield vaccine, Maldives looks elsewhere


IndiaTimes - Published

Covid-19: Government plans 1 crore daily vaccines from middle of July

The Centre plans to ramp up vaccination against Covid-19 on a “mission mode”, targeting an average of around 1 crore inoculations per day from around mid-July or August as vaccine supplies are..
IndiaTimes - Published

Centre creating 'artificial scarcity' of Covid vaccines to benefit Bharat Biotech, SII: AAP


IndiaTimes - Published

Serum Institute of India, Bharat Biotech producing minimum 8 crore doses/month, yet only 5 crore will be given by May-end

The government in an affidavit in the Supreme Court earlier this month averred that Serum Institute of India (SII) was producing 6.5 crore doses of Covishield a month and Bharat Biotech was producing 2..
IndiaTimes - Published

Serum Institute disassociates itself from its executive's remarks on Covid vaccination drive


IndiaTimes - Published

Never exported vaccines at the cost of people of India: SII

Defending its decision to export vaccines, Serum Institute of India (SII) said on Tuesday that it was based on several factors, including the build-up of a large stockpile in January, while cases were..
IndiaTimes - Published

Serum Institute CEO Adar Poonawalla finally breaks silence on export of vaccines

"Our government extended support wherever possible during this period," Serum Institute said in a statement.
DNA - Published

WHO reminds Serum Institute of its Covax commitments amidst devastating Covid-19 outbreak, soaring demand in India

WHO chief Tedros Adhanom Ghebreyesus has said that once the devastating Covid-19 outbreak in India recedes, the Serum Institute of India will need to "get back on track and catch up" on its delivery..
IndiaTimes - Published

No financial aid given to SII & Bharat Biotech: Govt in SC


IndiaTimes - Published

Govt rejects SII plea to export 50 lakh doses of Covishield to UK

Despite the international pressure and several rounds of negotiations by Serum Institute of India (SII), the government has turned down the request from SII to export 50 lakh doses of Covishield to UK..
IndiaTimes - Published

At Rs 700-Rs 1,500, price of Covid vaccine in India’s private sector among costliest

From Rs 250, the cost of vaccines in the private sector has shot up by up to six times. It now ranges from Rs 700-900 for Covishield manufactured by the Serum Institute of India (SII) and Rs..
IndiaTimes - Published

Plea in Bombay HC seeks Z-plus security for SII CEO Adar Poonawalla


IndiaTimes - Published

Ahead of India-UK summit, Boris Johnson announces 1 billion pound trade deal

The UK-India trade deals include an investment of 240 million pounds by the Pune-based Serum Institute of India (SII).
DNA - Published

Serum, Bharat Biotech got advance of Rs 2,500 crore for 16 crore doses, says government

The government on Monday said it had paid an advance of over Rs 2,500 crore to Serum Institute of India and Bharat Biotech for supply of 16 crore doses of Covid vaccine between May and July. While..
IndiaTimes - Published

Not possible to ramp up COVID vaccine production overnight: SII CEO Adar Poonawalla

Adar Poonawalla issued a statement after some of his comments on vaccine production were misinterpreted.
DNA - Published Also reported by •IndiaTimes

Media reports alleging Centre hasn't placed any fresh order for Covid-19 vaccines incorrect: Health ministry

"The news reports suggest that the last order placed with the two vaccine makers (100 million doses with SII and 20 million doses with Bharat Biotech) was in March 2021. These media reports are..
IndiaTimes - Published

Serum Institute of India CEO Adar Poonawalla makes BIG statement over COVID-19 vaccine shortage

According to a Financial Times report, SII CEO said that production of vaccines would increase in July from about 60-70 million to 100mln per month.
DNA - Published

Serum Institute CEO Adar Poonawalla: Will return to India in a few days

"Had an excellent meeting with all our partners & stakeholders in the UK. Meanwhile, pleased to state that Covishiled's production is in full swing in Pune. I look forward to reviewing operations upon..
IndiaTimes - Published

Serum Institute of India CEO Adar Poonawalla flies to London to after receiving 'threats' from CMs, corporates leaders

Poonawalla said that he is planning to stay in the UK for a long time because of constant threats he's getting from CMs and other corporate leaders.
DNA - Published


 Page 1  〉